Wire open Last filed ASC30 diabetes trial lowers HbA1c against placebo in 12 week Phase 2 study RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news, filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

UrgentTRLNews

ASC30 diabetes trial lowers HbA1c against placebo in 12 week Phase 2 study

Ascletis Pharma says its oral small molecule GLP 1 drug ASC30 lowered HbA1c by up to 1.7 points more than placebo in a 13 week U.S. Phase 2 study of 100 adults with type 2 diabetes. The data come from a press release and have not been peer reviewed.

HONG KONG

1.7 pointsPlacebo adjusted HbA1c drop at 12 weeks in the lowest and highest dose groups, per Ascletis
  1. What's newAscletis Pharma said its daily oral GLP 1 drug ASC30 met the main goal of a 13 week U.S. Phase 2 trial in 100 adults with type 2 diabetes, lowering HbA1c 1.6 to 1.7 points more than placebo at 12 weeks.
  2. Why it mattersASC30 is a small molecule pill rather than a peptide, part of a growing group of oral GLP 1 candidates. The early numbers are company reported, short term and limited to one on treatment analysis.
  3. What's nextAscletis plans a Phase 3 diabetes program with slower dose increases. Its AURORA Phase 3 obesity trials are enrolling about 4,600 people, with topline data expected by the company in the third quarter of 2028.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. TRL · 28 Oct 2026Lilly said retatrutide beat Ozempic at its highest approved diabetes dose in the Phase 3 TRANSCEND-T2D-2 trial, cutting A1C by 2.2 points against 1.8 and weight by up to 20.9% against 9.4% at 80 weeks.
  2. TRL · 28 Oct 2026Vanda Pharmaceuticals said its oral NK1 blocker Nereus (tradipitant) met both main goals in Phase 3 Study 3601, with 43.0% vomiting on the drug against 58.5% on placebo after an untitrated semaglutide dose.
  3. SAF · 28 Oct 2026Federal suits alleging Eli Lilly and Novo Nordisk failed to warn of vision loss and gut injury from GLP 1 drugs are pooled in two dockets in the Eastern District of Pennsylvania, MedShadow reported.
  4. REG · 28 Oct 2026The FDA approved Awiqli (insulin icodec-abae) for children aged 10 and older with type 2 diabetes on October 23, 2026, making it the first once weekly insulin for this age group.
  5. TRL · 28 Oct 2026Two Phase 3 trials published in NEJM found retatrutide cut breathing pauses in 691 adults with moderate to severe obstructive sleep apnea and overweight or obesity over 80 weeks, with and without type 2 diabetes.

By the numbers

The one figure each story turns on.

28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty-liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Head to head, tirzepatide beats semaglutide on weight loss 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 200+Peptide related hospitalisations in NSW in September 2026, up from five in July 2025, as cited by the authors SAF · 27 OCT · Peptide injectors need needle programs and safety advice say Queensland researchers 6 of 7Peptides the FDA compounding advisory committee backed for the 503A Bulks List in July 2026 SAF · 26 OCT · JAMA Viewpoint warns peptide compounding vote threatens the FDA approval system

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Copies, risks and rules

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Oct 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Oct 2026

  • 22 DECThe first GLP-1 pill for weight management gets the green light
  • 07 AUGThe weight-loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Oct 2026

  • 24 NOVSemaglutide fails to slow Alzheimer's in two large trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators9
TRLTrials19
INDIndustry6
SAFSafety13
EXPExplainers2

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator12
  • Journal9
  • Company release14
  • Conference6
  • Our newsroom8